Vanguard Group Inc Humanigen, Inc Transaction History

Vanguard Group Inc

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$0.13 - $0.2 $131,191 - $201,833	1,009,167 Added 144.0%	1,709,967 $256,000
Q4 2022 Feb 10, 2023	SELL	$0.09 - $0.2 $5,519 - $12,264	-61,323 Reduced 8.05%	700,800 $84,000
Q3 2022 Nov 14, 2022	SELL	$0.15 - $3.02 $253,899 - $5.11 Million	-1,692,661 Reduced 68.95%	762,123 $137,000
Q2 2022 Aug 12, 2022	BUY	$1.76 - $3.33 $45,406 - $85,910	25,799 Added 1.06%	2,454,784 $4.35 Million
Q1 2022 May 13, 2022	SELL	$1.81 - $3.97 $117,534 - $257,795	-64,936 Reduced 2.6%	2,428,985 $7.31 Million
Q4 2021 Feb 14, 2022	SELL	$3.66 - $8.22 $1.06 Million - $2.38 Million	-289,391 Reduced 10.4%	2,493,921 $9.28 Million
Q3 2021 Nov 12, 2021	BUY	$5.93 - $17.83 $3.19 Million - $9.6 Million	538,648 Added 24.0%	2,783,312 $16.5 Million
Q2 2021 Aug 13, 2021	BUY	$13.54 - $22.74 $30.4 Million - $51 Million	2,244,664 New	2,244,664 $39 Million

558K

Ticker HGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,661,000
Description
Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response called ?cytokine storm'. Lenzilumab is an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF). The company is developing lenzilumab as a treatment for cytokine storm associated with...

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

Stay updated on Vanguard Group Inc with notifications on news.